“We continue to execute on the submission of our BLA and are well positioned for potential revenue in 2020, subject to final approval. Our team is working diligently to complete the clinical and CMC portions, which represent the remaining two components of the BLA. We are also currently evaluating certain licensing opportunities relating to the commercialization of leronlimab upon approval,” added Dr. Pourhassan.

That's from 3/18/19. So I take it the first sections were approved from the rolling submission started in 2019. That leaves clinical and CMC. Today's release said it wasn't clinical.

Hopefully it won't take that long to correct.